BRD4354 Is a Potent Covalent Inhibitor against the SARS-CoV-2 Main Protease-Reference-Cited by-同舟云学术

BRD4354 Is a Potent Covalent Inhibitor against the SARS-CoV-2 Main Protease

Published:2024-02-08 Issue: Volume: Page:
ISSN:0006-2960
Container-title:Biochemistry
language:en
Short-container-title:Biochemistry

Author:

Sheng Yan J.¹^ORCID,Kuo Syuan-Ting A.¹,Yang Tingyuan¹,Zhang Hanyuan E.¹,Russell David H.¹^ORCID,Yan Xin¹^ORCID,Xu Shiqing¹²^ORCID,Liu Wenshe R.¹³⁴⁵^ORCID,Fierke Carol A.⁶^ORCID

Affiliation:

1. Department of Chemistry, Texas A&M University, College Station, Texas 77843, United States

2. Department of Pharmaceutical Sciences, Irma Lerma Rangel College of Pharmacy, Texas A&M University, College Station, Texas 77843, United States

3. Department of Biochemistry and Biophysics, Texas A&M University, College Station, Texas 77843, United States

4. Institute of Biosciences and Technology and Department of Translational Medical Sciences, College of Medicine, Texas A&M University, Houston, Texas 77030, United States

5. Department of Cell Biology and Genetics, College of Medicine, Texas A&M University, College Station, Texas 77843, United States

6. Department of Biochemistry, Brandeis University, Waltham, Massachusetts 02453, United States

Funder

Welch Foundation

Division of Intramural Research, National Institute of Allergy and Infectious Diseases

National Institute of Biomedical Imaging and Bioengineering

Texas A and M University

National Institute of General Medical Sciences

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.biochem.3c00685

Reference29 articles.

1. WHO Coronavirus (COVID-19) Dashboard. https://covid19.who.int/ (accessed 2023-08-16).

2. Pfizer Announces Additional Phase 2/3 Study Results Confirming Robust Efficacy of Novel COVID-19 Oral Antiviral Treatment Candidate in Reducing Risk of Hospitalization or Death. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-additional-phase-23-study-results (accessed 2023-08-16).

3. An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment

4. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

5. One Year of SARS-CoV-2: How Much Has the Virus Changed?